Drug intelligence / Profile preview

MIL62 + lenalidomide

Development stage: Unknown
Lead developer: Mabworks Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

MIL62 + lenalidomide is a combination therapy under investigation for the treatment of relapsed or refractory indolent non-Hodgkin lymphomas, specifically follicular lymphoma (FL) and marginal zone lymphoma (MZL). MIL62 is a novel third-generation, glycoengineered anti-CD20 monoclonal antibody designed to enhance antibody-dependent cell cytotoxicity. Lenalidomide is an immunomodulatory agent that alters cytokine production, enhances T-cell co-stimulation, and increases natural killer cell-mediated cytotoxicity; it also modulates the cullin ring E3 ubiquitin ligase complex by binding to cereblon and promoting degradation of key B-cell transcription factors. The combination aims to improve efficacy in B-cell malignancies by targeting both tumor cells directly (via CD20) and modulating the immune response[3][5][6][7][8].

Brand names: Revlimid
Other names: None

Targets

CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on MIL62 + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIL62 + lenalidomide.

Explore the full profile